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Abstract 
Background: Staphylococcus aureus is one of the causes of both community and healthcare-associated bacteremia. 
The attributable mortality of S. aureus bacteremia (SAB) is still higher and predictors for mortality and clinical out-
comes of this condition are need to be clarified. In this prospective observational study, we aimed to examine the 
predictive factors for mortality in patients with SAB in eight Turkish tertiary care hospitals.
Methods: Adult patients with signs and symptoms of bacteremia with positive blood cultures for S. aureus were 
included. All data for episodes of SAB including demographics, clinical and laboratory findings, antibiotics, and out-
come were recorded for a 3-year (2010–2012) period. Cox proportional hazard model with forward selection was used 
to assess the independent effect of risk factors on mortality. A 28-day mortality was the dependent variable in the Cox 
regression analysis.
Results: A total of 255 episodes of SAB were enrolled. The median age of the patients was 59 years. Fifty-five percent 
of the episodes were considered as primary SAB and vascular catheter was the source of 42.1 %. Healthcare associ-
ated SAB was defined in 55.7 %. Blood cultures yielded methicillin-resistant S. aureus (MRSA) as a cause of SAB in 
39.2 %. Initial empirical therapy was inappropriate in 28.2 %. Although overall mortality was observed in 52 (20.4 %), 
28-day mortality rate was 15.3 %. Both the numbers of initial inappropriate empirical antibiotic treatment and the 
median hours to start an appropriate antibiotic between the cases of fatal outcome and survivors after fever onset 
were found to be similar (12/39 vs 60/216 and 6 vs 12 h, respectively; p > 0.05). High Charlson comorbidity index (CCI) 
score (p = 0.002), MRSA (p = 0.017), intensive care unit (ICU) admission (p < 0.001) and prior exposure to antibiot-
ics (p = 0.002) all were significantly associated with mortality. The Cox analysis defined age [Hazard Ratio (HR) 1.03; 
p = 0.023], ICU admission (HR 6.9; p = 0.002), and high CCI score (HR 1.32; p = 0.002) as the independent predictive 
factors mortality.
Conclusions: The results of this prospective study showed that age, ICU stay and high CCI score of a patient were the 
independent predictors of mortality and MRSA was also significantly associated with mortality in SAB.
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Background
Staphylococcus aureus is a leading cause of both commu-
nity and healthcare -associated bacteremia and competes 
with Escherichia coli for the leading cause of community-
acquired bacteremia. S. aureus bacteremia (SAB) can 
seed to virtually any body site and result in complications 
that may further result in severe disease, significant mor-
bidity and death [1].
SAB places a substantial burden on health care sys-
tems with its high mortality rates of around 20–30  % 
and morbidity rates [2, 3]. This burden is increased by 
life-threatening complications, including infective endo-
carditis (IE) and other serious metastatic infections com-
plications that more frequently require intensive care 
unit (ICU) admission and carry poor prognosis because 
of the anatomic site or the difficulty in reaching a timely 
diagnosis [4–6]. It is therefore imperative to know which 
patients are prone to SAB and its complications, varia-
tion of laboratory findings during SAB and its predictors 
of mortality.
Data regarding the characteristics of SAB in Turkey is 
insufficient and most of them are retrospective charac-
ter [7–9]. For this reason, this prospective multicenter 
observational study aimed to identify predictors of mor-
tality in patients with SAB in Turkish hospitals. The most 
common sources of SAB, its complications, and treat-




This prospective, multicenter cohort study involved a 
3-year period from January 2010 to December 2012. A 
thorough patient data collection form was sent and data 
were collected prospectively from eight participant cent-
ers in Turkey. All consecutive patients (15 years and over) 
with signs and symptoms of bacteremia with positive 
blood cultures for S. aureus were included in this study. 
Only the first clinically significant episode of infection 
with SAB for each patient was included in the analysis. 
Patients who had SAB as part of a polymicrobial blood-
stream infection were excluded. Clinical Research Eth-
ics Committee of Medipol University (Istanbul, Turkey) 
approved this study.
Clinical and laboratory analyses and follow‑up period
Patients with SAB were identified from microbiology lab-
oratory records by daily visits. Patients were followed in 
the participant centers until discharge or death. Baseline 
characteristics, treatment regimens, outcome and other 
factors were recorded prospectively.
Usually two or more sets of blood cultures were 
obtained simultaneously from different sites and repeated 
when needed. Blood specimens were cultured on vials of 
automatic systems for a 7-day period in different centers, 
mainly by the BACTEC 9240 system (Becton–Dickinson, 
Maryland, USA). All S. aureus isolates were identified 
by standard laboratory methods at the clinical microbi-
ology laboratory of participating centers. Antimicrobial 
susceptibilities of the isolates including oxacillin and van-
comycin were determined by using disk diffusion test or 
automated systems according to the criteria of the Clini-
cal and Laboratory Standards Institute (CLSI) [10]. Dur-
ing the study period all S. aureus isolates were submitted 
to the microbiology laboratory of Istanbul Medipol Uni-
versity for further verification. The identification and 
antimicrobial susceptibilities of isolates were performed 
by using Vitek 2 (bioMérieux, Marcy L’E`toile, France) 
bacterial identification and antimicrobial susceptibility 
testing (AST) system. Other specimens including pus, 
wound swabs, sputum, tracheal aspirates, bronchoalveo-
lar lavage fluid, synovial fluid and central venous catheter 
(CVC) tips were also cultured to determine the source of 
SAB when necessary.
In order to determine the involvement of the cardio-
vascular system, transthoracic echocardiography (TTE) 
was performed for all patients when blood cultures were 
positive for S. aureus. Transesophageal echocardiography 
(TEE) was also performed for patients suspected of IE 
with negative TTE findings. Routine laboratory analyses 
and chest X-rays were also performed for all patients. The 
validated Charlson comorbidity index (CCI) score, which 
stratifies the associated diseases into an ordinal scale, was 
used to evaluate comorbidity in 28-day mortality among 
the patients [11]. Empirical antibiotic treatment was ini-




Bacteremia was defined as the presence of ≥1 positive 
blood culture for S. aureus in a patient who had signs 
and symptoms consistent with an infection [12]. SAB 
was classified as community-acquired if S. aureus was 
isolated from blood cultures drawn within 48 h of admis-
sion of a patient with suggestive symptoms or signs of 
an infection after hospital admission, if the patient was 
not transferred from another hospital, and if the patient 
had any symptoms or signs suggestive of infection at 
admission. Otherwise, SAB was considered to have been 
health-care associated [13]. In the presence of a labora-
tory-confirmed bloodstream infection, primary bactere-
mia was considered if the organism cultured from blood 
is not related to an infection at another site. Otherwise, 
bacteremia was considered secondary. The diagnosis 
of Systemic Inflammatory Response Syndrome (SIRS) 
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was made according to the criteria of the Surviving sep-
sis campaign and the presence of SIRS accompanied by 
infection was diagnosed as sepsis [14]. Prior admission 
history was defined as hospitalization within 90  days 
before the onset of SAB.
Foci of bloodstream infection
The primary foci of infection were determined using 
the following definitions. Catheter-related bloodstream 
infection (CR-BSI) was defined as SAB in any patient 
who has an intravascular device with ≥1 positive blood 
culture result obtained from the peripheral vein and no 
apparent source for SAB except the catheter. A micro-
biological proof of a catheter infection was warranted 
as either a positive result of a semiquantitative (>15 cfu 
per catheter segment) catheter culture whereby the 
same organism is isolated from a catheter segment and a 
peripheral blood culture, or a differential time to positiv-
ity (>2 h between catheter vs peripheral blood). Soft tis-
sue infection was considered the source of SAB in cases 
where patients (a) had a culture of S. aureus from a tissue 
or a drainage specimen from the affected site and (b) had 
signs of infection [13]. Surgical site infection was defined 
according to the definitions of the Centers for Disease 
Control and Prevention (CDC) [15].
Antibiotic treatment and outcome
Empirical antibiotics were prescribed by the primary care 
physician. Appropriate antibiotic treatment was consid-
ered if the empirical therapy provided after the onset of 
bacteremia symptoms included at least one antibiotic to 
which the isolate was susceptible (a glycopeptide or a lipo-
peptide for methicillin resistant S. aureus (MRSA); beta-
lactam/beta-lactamase inhibitor (BL/BLI) combination or 
cefazolin for methicillin susceptible S. aureus (MSSA).
De-escalation of antibiotic treatment was defined as a 
switch to a narrower spectrum agent and it was consid-
ered when an antibiotic with activity against MRSA was 
replaced by an antibiotic with activity against MSSA. 
Escalation of antibiotic treatment was defined as either 
the addition of a new antibiotic or a switch on an agent 
with MRSA activity.
The primary endpoint of this study was 28-day all-
cause in-hospital mortality. Bacterial eradication was 
defined as the absence of S. aureus in repeated blood cul-
tures during therapy and no evidence of recurrent SAB 
during a follow-up of 28  days, bacterial recurrence was 
defined as clinical resolution of signs and symptoms of 
infection during therapy but recurrent SAB during fol-
low-up period. Treatment failure was defined as continu-
ation of signs and symptoms of infection despite therapy 
or death.
Statistical analysis
Statistical analysis was performed with Stata 13.1 (Stata 
Corp. LP, USA). Descriptive statistics such as means, 
standard deviation, medians, interquartile ranges (IQRs), 
frequencies, and percentages were collected. Compari-
sons between the continuous variables were performed 
using independent-samples t tests or Mann–Whitney 
U tests as appropriate, while comparisons between cat-
egorical variables were performed by Pearson’s Chi 
squared or Fisher’s exact tests. Cox proportional haz-
ard model was used to assess the independent risk fac-
tors on mortality. Variables that have a significance value 
equal or less than 0.1 in the univariate analysis or vari-
ables that have been reported significant in the literature 
were included in the Cox proportional hazard analysis. 
Proportionality was controlled. Relative risks (RRs) and 
hazard ratios (HRs) with corresponding 95 % confidence 
intervals (95 % CIs) were calculated in order to describe 
the strength and direction of the association. Difference 
according to ICU stay was assessed by Kaplan–Meier 
survival curves and log-rank test. All statistical tests 




During the study period 266 episodes of SAB were con-
firmed. Eleven were excluded from the analysis due to 
SAB as part of a polymicrobial bloodstream infection. 
Therefore, 255 patients (159 male, 96 female) with clini-
cally significant of SAB episodes were analyzed. The 
median (IQR) age was 59 (45, 70) years. During the study 
period, death occurred in 52 (20.4  %) out of 255 cases. 
However a 28-day of mortality rate was 15.3 % (39 out of 
255) for this study. Main descriptive characteristics of the 
255 patients are given in Table 1. The number of patients 
over 65  years was 93 (36.5  %). The commonest comor-
bid condition was diabetes mellitus (24.7  %) among the 
cases. Fever (>38  °C) was present in 230 (90  %), tachy-
cardia (>100 beats/min) in 191 (74.9 %), tachypnea (>20 
breaths/min) in 147 (57.7  %), hypotension (arterial ten-
sion <90  mmHg) in 91 (35.7  %), and altered conscious-
ness in 41 (16.1 %) patients at the time of blood culture 
collection. The most common coexistent factors for 
SAB among the patients were the presence of periph-
eral venous catheter (64.7  %) and CVC (51  %). Further, 
107 (42  %) patients stayed in the ICU and 101 (39.6  %) 
patients had prior antibiotic use a month before of a 
blood culture was drawn. Routine laboratory analyses 
at the time of diagnosis revealed leukocytosis (>10,000/
mm3) in 180 (70.6 %) and thrombocytopenia (<150,000/
mm3) in 93 (36.5 %) out of 255 patients, respectively.
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Clinical characteristics
Of the 255 patients, 100 (39.2 %) had MRSA bacteremia 
and 155 (60.8  %) had MSSA bacteremia. One hundred 
forty-one patients (55  %) were considered as primary 
SAB. Of all remaining 114 (45 %) patients with secondary 
SAB; 48 (42.1 %) patients were diagnosed as CR-BSI, 30 
(26.3 %) patients were diagnosed as skin and soft tissue 
infection (SSTI), 18 (15.8  %) were diagnosed as IE, and 
the remaining 18 (15.8 %) were diagnosed as surgical site 
infections (SSIs) (Data not shown).
Microbiological and routine laboratory characteristics
A total of 515 (84.8  %) out of 607 blood cultures taken 
from the 255 patients grew S. aureus. The median (IQR) 
culture sets taken from the patients was 2 (2, 3) and the 
median (IQR) time to positivity of blood cultures of 170 
patients with SAB was 24 (18, 48) hours. The average of 
55.7  % of the episodes was healthcare-associated SAB. 
Ninety-five (95 %) of 100 MRSA and 47 (30.3 %) of 155 
MSSA isolates were considered as health-care associated. 
Five percent of MRSA and 69.7 % of MSSA isolates were 
also considered as community-acquired. Routine labora-
tory parameters for patients who died and survived are 
compared in Table  2. The median highest white blood 
cells (WBC) count (p = 0.026), the mean lowest platelet 
counts (p  <  0.0001) and the mean blood albumin levels 
(p  =  0.0001) were significantly associated with death. 
The groups did not differ in terms of lowest WBC counts, 
highest serum creatinine, liver enzymes, alkaline phos-
phatase and C-reactive protein (CRP) levels (p > 0.05 for 
all comparisons).
Characteristics of fatal and survivor patients
The results of evaluated demographical and clinical data 
in a univariate analysis are given in Table 3. ICU admis-
sion (p  <  0.001), MRSA as a cause of SAB (p  =  0.017) 
and history of exposure to antibiotics within last 30 days 
(p =  0.002) were all significantly associated with death. 
Although the number of patients having a minimum of 
one comorbid condition between the groups were the 
same (p =  0.102), the CCI scores were found to be dif-
ferent and fatal cases significantly had higher CCI score 
(p =  0.013). Both fatal and survivor groups were found 
to be very similar in terms of age and gender and initial 
inappropriate empirical antibiotic treatment (p > 0.05 for 
all comparisons). The median hours to start an appro-
priate antibiotic after fever onset between the fatal and 
survivor groups was also found to be not significant 
(6 vs 12  h; p  =  0.437). Furthermore, the median (IQR) 
time to appropriate antibiotic after a positive culture 
for S. aureus was 16 (1, 96) hours in fatal group (n = 29) 
and it was 24 (1, 144) hours in survivor group (n = 131; 
p = 0.535) (Data not shown).
Complications of bacteremia
SAB resulted in complications in 24 (9.4  %) patients. 
Nine (37.5 %) patients developed pneumonia, 4 (16.7 %) 
patients developed vertebral osteomyelitis, 1 (4.2  %) 
patient developed splenic abscess, and one patient 
(4.2  %) developed endophthalmitis. The remaining 9 
(37.5 %) patients developed other metastatic suppurative 
Table 1 Descriptive characteristics of the cohort (N = 255)
WBC white blood cells
a Cancer chemotherapy, steroid treatment and others
b Cirrhosis, 9; Chronic alcoholism, 9; Connective tissue disorder, 6; Resident of 
elderly care center, 6; Alzheimer’s disease, 6; intravenous drug user, 2; Renal 
transplantation, 1
c Drowsiness and coma diagnosed by a physician
d A month prior to detection of S. aureus bacteremia
Variable Number Percent
Age >65 years 93 36.5
Comorbid diseases
 Diabetes mellitus 63 24.7
 Chronic renal failure 56 22.0
 Previous surgery 54 21.2
 Malignant diseases 53 20.8
 Skin disorder 51 20.0
 Immunosuppressive therapy in last 3 monthsa 32 12.6
 Burns 28 11.0
 Chronic obstructive pulmonary disease 11 4.1
 Congestive heart failure 11 4.1
 Cerebrovascular event 10 3.9
 Othersb 50 19.6
Clinical findings
 Fever (≥38 °C) 230 910
 Tachycardia (>100 beats/min) 191 74.9
 Tachypnea (>20 breaths/min) 147 57.7
 Hypotension (arterial tension <90 mmHg) 91 35.7
 Altered consciousnessc 41 16.1
Coexistent factors
 Peripheral venous catheter 165 64.7
 Central venous catheter 130 51.0
 Intensive care unit admission 107 42.0
 Prior antibiotic used 101 39.6
 Mechanical ventilation 80 31.4
 Prior hospitalization 78 30.6
 Endotracheal tube 73 28.63
 Tracheostomy 41 16.1
 Prior cardio-pulmonary resuscitation 28 11.0
Laboratory findings
 Leukocytosis (WBC count >10,000/mm3) 180 70.6
 Thrombocytopenia (platelet <150,000/mm3) 93 36.5
 Leukopenia (WBC <4000/mm3) 26 10.2
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complications. Four patients showed a recurrence of bac-
teremia following cessation of treatment.
Treatment and outcome
Following the assessment of the patients with SAB, 91 
patients received glycopeptides or lipopeptides (vanco-
mycin, teicoplanin, and daptomycin), 76 patients received 
BL/BLI combinations (ampicillin/sulbactam, cefoperazon/
sulbactam, piperacillin/tazobactam, ticarcillin/clavula-
nate), 40 patients received BL antibiotics (cefazolin, imipe-
nem or meropenem, ceftriaxone, cefuroxime, ceftazidime, 
cefepime, amoxicillin), 11 patients received intravenous 
linezolid and remaining 37 patients received various anti-
biotics as an empirical therapy. We were not able to show 
any differences regarding mortality between survivor and 
fatal groups based on the empirical antibiotics (p  >  0.05 
Table 2 Comparison of  routine laboratory parameters for  fatal and  survivor (28-day mortality) patients with  Staphylo-
coccus aureus bacteremia measured at the time of blood culture collection
Significant p values are presented as italics (p < 0.05)
IQR interquartile range, SD standard deviation, WBC white blood cells, CRP C-reactive protein, ALT alanine aminotransferase, AST aspartate aminotransferase, ALP 






Median (IQR) highest WBC (×109/L) 18.8 (11.7, 23.4) 13.7 (10, 17.9) 0.026 14 (10, 18.8)
Median (IQR) lowest WBC (×109/L) 8.8 (4.1, 13.3) 7.2 (5.4, 9.5) 0.287 7.3 (5.4, 9.6)
Mean ± SD (range) lowest platelet (×109/L) 110 ± 94 (17–461) 196 ± 102 (5–545) <0.0001 181 ± 106 (5–545)
Mean highest ± SD (range) BUN (mg/dL) 90 ± 72.2 (23–332) 65 ± 59.2 (7–383) 0.03 69.1 ± 61.8 (7–383)
Mean highest ± SD (range) creatinine (mg/dL) 2.1 ± 1.9 (0.3–6.7) 2.1 ± 2.5 (0.1–13.5) 0.929 2.1 ± 2.4 (0.1–13.5)
Mean highest ± SD (range) ALT (IU/L) 84.0 ± 246.6 (3–1497) 60.6 ± 106.5 (5–1160) 0.350 64.3 ± 137.6 (3–1497)
Mean highest ± SD (range) AST (IU/L) 177 ± 724 (6–4391) 69.2 ± 152.7 (6–1157) 0.062 86.1 ± 318.3 (6–4391)
Mean highest ± SD (range) GGT (IU/L) 106 ± 106.2 (6–422) 92.7 ± 111.3 (6–757) 0.613 94.5 ± 110.4 (6–757)
Mean highest ALP ± SD (range) (U/L) 177.6 ± 189 (46–686) 139.4 ± 119.8 (28–923) 0.221 144.2 ± 130.2 (28–923)
Mean lowest ± SD (range) albumin (g/dL) 2.5 ± 0.7 (1.1–4.6) 2.9 ± 0.6 (1.4–4.8) 0.0001 2.8 ± 0.7 (1.1–4.8)
Median (IQR) highest CRP (mg/L) 191.5 (131, 215) 171 (89, 218) 0.225 174 (101, 218)
Table 3 Comparison of variables between survivor and patients with fatal outcome (28-day mortality) (N = 255)
IQR interquartile range
Significant p values are presented as italics (p < 0.05)
a At least one comorbid condition per patient
b Within the last month at least for 3 days
Variable Fatal Survivor p value
(n = 39) (n = 216)
Median (IQR) age (years) 62 (53, 70) 59 (44, 70) 0.184
Gender, n (%) 0.552
 Man 26 (66.7) 133 (61.6)
 Woman 13 (33.3) 83 (38.4)
Median (IQR) time to appropriate antibiotic after fever onset (hours) 6 (2, 30) 12 (2, 27) 0.437
Inappropriate empirical antibiotic 12 (30.8) 60 (27.8) 0.703
Comorbid condition, n (%)a 34 (87.2) 160 (74.1) 0.102
Charlson comorbidity index score, n (%) 0.013
 Low (0–1) 9 (23.1) 100 (46.3)
 Medium (2–4) 19 (48.7) 85 (39.4)
 High (≥5) 11 (28.2) 31 (14.3)
Methicillin-resistant S. aureus, n (%) 22 (56.4) 78 (36.1) 0.017
Intensive care unit stay, n (%) 28 (71.8) 79 (36.6) <0.001
Exposure to antibiotics, n (%)b 24 (61.5) 77 (35.6) 0.002
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for all comparisons). Only the patients receiving empirical 
linezolid showed borderline statistical significance towards 
increased mortality (p = 0.05; RR = 2.4) (Table 4). Empiri-
cal antibiotic treatment was considered to be inappropri-
ate in 72 (28.2 %) patients. In overall, empirical antibiotics 
were modified in 66 (25.9  %) patients. The spectrum of 
empirical treatment was deescalated in 3 (5.9  %) fatal 
and in 17 (8.4  %) survivors (p =  0.773) and escalated in 
19 (36.5 %) fatal and in 27 (13.3 %) survivors (p < 0.0001) 
(Table  4). Bacterial eradication was achieved in 199 
patients while empirical antibiotic treatment failed in 39 
(100 %) fatal and in 11 (5.4 %) survivors (p < 0.0001). SAB 
recurred in 3 of the (7.7 %) fatal and 1 of the (0.5 %) survi-
vors (p = 0.028) (Data not shown).
Effects of empirical antibiotic treatment with respect to 
oxacillin susceptibility of S. aureus on 28-day mortality of 
our cohort are summarized in Table 5. Although inappro-
priate empirical therapy was associated with mortality in 
one-thirds of the patients in both MRSA (7/22) and MSSA 
(5/17) bacteremia groups, this effect was not statistically 
significant (p  >  0.05). Gentamicin was added to treat-
ment for various reasons in 15 patients. The overall 14-, 
28- and 60-day mortality rates were 11 % (28/255), 15.3 % 
(39/255), and 20.4  % (52/255) respectively. However 80 
(31.4 %) patients with severe sepsis or septic shock had a 
28-day mortality rate of 32.5 % (26 patients). Inappropriate 
empirical antibiotic treatment in 23 (28.8 %) of 80 patients 
was associated with 8 (34.8 %) deaths. Further, the median 
(IQR) time to appropriate antibiotic after a positive cul-
ture for S. aureus was 12 (3, 24) hours in patients with 
severe sepsis or septic shock and it was 10 (2, 36) hours in 
patients without severe sepsis or septic shock (p =  0.73) 
(data not shown). Among all patients who died, death 
was definitely attributed to SAB in 6/52 (11.5 %) patients, 
probably attributed to SAB in 20/52 (38.5 %) patients and 
to other reasons including underlying diseases in 21/52 
(40.3 %) patients. The exact cause of death was unidenti-
fied in the remaining 5/52 (9.6 %) patients.
In a multivariable Cox model the independent predic-
tors of 28-day all-cause of mortality were: age (HR 1.03; 
p = 0.023), ICU stay (HR 6.9; p = 0.002), and high CCI 
score (HR 1.32; p = 0.002) (Table 6). Kaplan–Meier sur-
vival estimates of patients with SAB regarding ICU stay is 
shown in Fig. 1.
Table 4 Comparison of survivor and fatal patients with Staphylococcus aureus bacteremia in regards to empirical antibi-
otic treatments and modifications (60-day mortality) (N = 255)
Peptide antibiotics: vancomycin, teicoplanin, and daptomycin
BL/BLI beta lactam/beta lactamase inhibitors, BL beta lactam antibiotics, CI confidence interval
Data are presented as n (%). Significant p values are presented as italics (p < 0.05)





Relative risk [95 % CI] p value
Empirical treatment options
 Peptide antibiotics 22 (42.3) 69 (33.9) 1.32 [0.81–2.15] 0.264
 BL/BLI 10 (19.2) 66 (32.5) 0.56 [0.29–1.06] 0.062
 BL 9 (17.3) 31 (15.3) 1.13 [0.59–2.12] 0.719
 Linezolid 5 (9.6) 6 (3.0) 2.36 [1.18–4.74] 0.05
 Othersa 6 (11.5) 31 (15.3) 1.1 [0.91–1.24] 0.495
Antibiotic modifications
 De-escalated 3 (5.9) 17 (8.4) 0.67 [0.26–2.19] 0.773
 Escalated 19 (36.5) 27 (13.3) 2.61 [1.64–4.17] <0.0001
 Unchanged 30 (57.6) 159 (78.3) 0.48 [0.29–0.76] 0.0024
Table 5 Appropriate empirical antibiotic use with  respect to  oxacillin susceptibility and  outcome of  Staphylococcus 
aureus bacteremia (28-day mortality)
Data presented as n (%) of row
Appropriate antibiotic Oxacillin‑resistant (N = 100) Oxacillin‑susceptible (N = 155)
Fatal Survivor p value Fatal Survivor p value
Yes 15 (25.4) 44 (74.6) 0.322 12 (9.7) 112 (91.3) 0.336
No 7 (17.1) 34 (82.9) 5 (16.1) 26 (83.9)
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Discussion
Staphylococcus aureus bacteremia is a common and serious 
infection with significant morbidity and mortality, especially 
in ICU patients [16]. It is difficult to determine the exact 
incidence of SAB, since prospective population-based sur-
veillance studies are infrequently performed. The annual 
incidence has been reported as low as 19.7/100,000 popula-
tion in Canada and 26/100,000 population in Sweden [17–
19], and as high as 50/100,000 population in the USA [20]. 
The difference could be due to infection control practices 
or variances in surveillance systems. Interestingly, the inci-
dence of SAB has generally been reported to be higher for 
males than for females, while some studies have shown an 
increased mortality for females [20, 21]. Sixty-two percent 
of our cohort was men and the mortality of SAB in men and 
women were 16.4 % and 13.5 %, respectively. We have not 
detected any gender difference in regard to outcomes.
The SAB episodes due to MSSA is generally predomi-
nate, especially in countries with a low prevalence of 
MRSA [17, 22]. Likewise, 60.8  % of our patients turned 
out MSSA when consecutive 255 patients with SAB 
were collected. Mortality of SAB has been reported 
to be declining steadily throughout the 20th century, 
probably as a result of greater understanding of SAB 
management. Case-mortality associated with hospital-
acquired and community-acquired SAB showed rate 
reductions of 43 and 23 %, respectively between 1981 and 
2000 (p = 0.0001) [17]. A previous prospective study sug-
gests 30-day all-cause mortality of 20.6 % which is signifi-
cantly associated with older age, and MRSA infection as 
we found in the cohort [23]. A recent prospective study 
that included patients with both community and health-
care-associated SAB between 2007 and 2011 reported 
30-day all-cause and infection-related mortalities of 25.8 
and 11.2 %, respectively [24]. Our cohort showed 28-day 
all cause and infection-related mortalities of 15.3 and 
10.2 %, respectively which may suggest that mortality of 
SAB may be further decreasing. However, prospective 
data from larger cohorts are required to resolve this issue. 
Age has been confirmed as a strong independent predic-
tor of mortality in many studies as we found [23, 25, 26]. 
The mortality rate was found to be increased from 6 % in 
young individuals (<15 years old) to 57 % in adults older 
than 85 years of age by Lamagni et al. [25].
It is well known that presence of comorbidities can 
influence the patient outcome. The SAB mortality has 
been accepted to increase with the presence of one or 
multiple comorbidities including immunosuppression, 
cirrhosis, malignancy, and chronic renal failure [17, 27–
29]. This study showed that the number of patients hav-
ing a minimum of one comorbid condition between the 
fatal and survivor groups were the same. However CCI 
scoring for the assessment of the severity of illness indi-
cator [11] revealed that cases with fatal outcome had 
significantly high CCI score suggesting these cases had 
more severe illness. However, other studies detected any 
difference in outcomes for patients with comorbidities 
[30–34].
Ninety-five percent of MRSA were isolated from 
healthcare-associated SABs, while 70  % of MSSA were 
isolated from community-acquired SABs in our cohort. 
According to current cohort studies, the setting of SAB 
onset, whether health-care associated or community-
acquired, does not seem to have an effect on patient 
Table 6 Cox proportional hazard model for 28-day mortality
CI confidence interval, significant p values are presented as italic (p < 0.05)
a Within last 30 days at least for 3 days
Variable Hazard ratio [95 % CI] p value
Age (per year increase) 1.03 [1.0–1.05] 0.023
Intensive care unit stay 6.9 [2.02–23.6] 0.002
Time to appropriate antibiotic after fever onset (hours) 1.0 [0.99–1.02] 0.833
Exposure to antibioticsa 1.98 [0.73–5.42] 0.181
Methicillin-resistant S. aureus 0.99 [0.33–3.0] 0.991
Charlson comorbidity index score 1.32 [1.1–1.58] 0.002
Fig. 1 Kaplan–Meier survival estimates of patients regarding inten-
sive care unit (ICU) stay
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outcomes [12, 34, 35]. Likewise, we were not able to show 
any difference in mortality rates based on the setting of 
SAB onset. However, advent of community acquired 
(CA)-MRSA may change the equation, which remains to 
be shown in future studies. Currently CA-MRSA isolates 
are very rarely reported in Turkey [36].
Patients with SAB developing sepsis or septic shock 
have mortality rates of ranging between 38 and 86 %, and 
are strongly associated with worse outcomes [32, 37]. 
Eighty (31.4 %) patients developed severe sepsis or sep-
tic shock in our cohort and 28-day mortality was 32.5 % 
for such cases. A previous retrospective Turkish study 
from a single center reported 41.7 % of mortality rate for 
patients with septic shock [38].
The impact of methicillin resistance on mortality of 
SAB has been examined by a number of studies. The 
results of the majority of these studies are conflicting. 
A well-designed meta-analysis by Cosgrove et  al. [39] 
showed that mortality rates for MRSA bacteremia were 
significantly higher than that of MSSA bacteremia (OR, 
1.93; 95 % CI, 1.54–2.42; p < 0.001). Methicillin resistance 
was found to be an independent risk factor of mortality 
in our cohort. This finding could be explained by differ-
ences in empirical prescribing [40] or poor vancomycin 
efficacy [41]. However, a recent study by Wolkewitz et al. 
[42] showed that there is only a small and statistically 
insignificant difference between mortality rates of MRSA 
and MSSA bacteremia when length of hospital stay was 
adjusted. Similarly a large prospective study by Melzer 
et  al. [43] also revealed that MRSA bacteremia was not 
associated with increased mortality after adjustments for 
various host confounders including comorbidities, age, 
and severity of illness.
Heteroresistant vancomycin-intermediate S. aureus 
(hVISA) should also be considered as a factor for SAB 
mortality. Although mortality rate of SAB due to hVISA 
has been reported as high as 75 % in earlier studies [44], 
overall, hVISA bacteremia is not associated with an 
increased mortality rate [45]. One of the limitations in 
our study was that antimicrobial susceptibility testing for 
all S. aureus isolates was performed by disk diffusion or 
commercial automated systems, which tend to undercall 
resistance [46]. Therefore we are not able to discuss any 
effect of hVISA on mortality of our patients.
Complications of SAB are common, occurring at rates 
that range from 11 to 53 % [6, 47]. A recent study eval-
uating predictive factors associated with the develop-
ment of metastatic infection following SAB revealed a 
delay in appropriate antimicrobial treatment of >48  h, 
persistent fever for >72  h after starting antibiotic treat-
ment and lowest CRP levels of >3 mg/dL as significant in 
multivariate analysis [48]. Some complications more fre-
quently require intensive care admission and carry poor 
prognosis because of the anatomic site or the difficulty in 
reaching a timely diagnosis.
Staphylococcus aureus is one of the only causes of IE in 
structurally normal heart valves [49], and it is the lead-
ing cause of IE in several countries [5]. A large-scale pro-
spective, multicenter, observational study showed that 
13 % of patients with SAB had IE [50]. We found a similar 
incidence of 15.8 % in our study. Patients with hospital-
acquired SAB have a lower incidence of IE than those 
with community-acquired SAB (2–17  %) as expected 
[50].
For the management of SAB, no antimicrobial agent 
was shown to result in better patient outcomes and the 
initial therapy was inappropriate in 28.2  % of 255 SAB 
episodes in our cohort. This was an unexpected observa-
tion because inappropriate antibiotic treatment was iden-
tified as an independent predictive factor for mortality, as 
in previous studies [32, 33]. A previous study performed 
in 819 MRSA bacteremia episodes showed that inappro-
priate antibiotic had no effect on mortality [30]. Early 
administration of broad-spectrum antimicrobials has 
always been stressed and advocated in surviving sepsis 
campaigns [51], however, evidence for this recommen-
dation has been mainly provided in patients with septic 
shock [52–55].
In addition to inappropriate initial empirical antibi-
otic, our study did not show delayed time to appropri-
ate antibiotic after fever onset as a predictor of mortality. 
This finding could be explained by an initial treatment 
selection bias. However, there are other studies that are 
unable to detect a mortality difference regarding timing 
of appropriate empirical therapy [32, 37]. When Lodise 
et  al. looked at as to which patient subgroups would 
actually benefit greatest from timing of empirical antibi-
otics, they found that patients with severe disease ben-
efitted most [56]. Only a minority of the patients in our 
cohort had severe sepsis and the remaining majority of 
patients might have neutralized the impact of delayed 
appropriate antimicrobial treatment in that group. 
About 80  % of patients with SAB do not suffer from 
severe sepsis or septic shock [57]. Patients with SAB 
caused by MRSA may be at increased mortality risk of 
being treated inadequately when MRSA is not covered 
in empiric antimicrobial regimens. However, community 
acquired MRSA is very rare in Turkey and the incidence 
of S. aureus infections is rapidly declining in Turkish 
ICUs [58]. Due to all the reasons stated above, our study 
may not have shown significant differences in outcome 
between patients with early and delayed appropriate 
antimicrobial treatments.
Intensive care unit stay was one of the independent 
risk factors of mortality in our study. Either transit to an 
ICU [59] or the acquisition of SAB in the ICU [12] has 
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been found to be independent predictors of mortality, 
probably since they were surrogate markers for infection 
severity.
In conclusion, the data from this prospective study per-
formed in Turkish patients demonstrated several prog-
nostic factors for SAB mortality including age, ICU stay 
and high CCI scores. Furthermore, methicillin resistance 
may be a risk factor for mortality of patients with SAB. 
In contrast, inappropriate initial empirical antibiotics and 
delays of starting the appropriate antibiotics within a few 
hours may not have any impact on mortality. In order to 
proper management of SAB, clinicians should be aware 
of patients with one or some of the above mentioned 
predictors.
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